STOCKHOLM, Sweden--(BUSINESS WIRE)--April 26, 2006--Medivir (STO:MVIRB) :
Medivir develops drugs against major, widespread diseases based on proteases as targets. The objective is to be a sustainable, profitable research-based pharmaceutical company with products on the market developed in-house. Medivir is located in Huddinge, Sweden and at Chesterford Research Park, Essex, UK.
